<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39451754</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1718-7729</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Current oncology (Toronto, Ont.)</Title><ISOAbbreviation>Curr Oncol</ISOAbbreviation></Journal><ArticleTitle>Ritonavir's Evolving Role: A Journey from Antiretroviral Therapy to Broader Medical Applications.</ArticleTitle><Pagination><StartPage>6032</StartPage><EndPage>6049</EndPage><MedlinePgn>6032-6049</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/curroncol31100450</ELocationID><Abstract><AbstractText>Ritonavir is a protease inhibitor initially developed for HIV treatment that is now used as a pharmacokinetic booster for other antiretrovirals due to it being a cytochrome P450 3A4 enzyme and P-glycoprotein inhibitor. Consequently, ritonavir is of special interest for repurposing in other diseases. It had an important role in battling the COVID-19 pandemic as a part of the developed drug Paxlovid<sup>®</sup> in association with nirmatrelvir and has shown effects in hepatitis and other pathogenic diseases. Ritonavir has also shown promising results in overcoming drug resistance and enhancing the efficacy of existing chemotherapeutic agents in oncology. Evidence of cancer repurposing potential was demonstrated in cancers such as ovarian, prostate, lung, myeloma, breast, and bladder cancer, with several mechanisms of action presented. In vitro studies indicate that ritonavir alone can inhibit key pathways involved in cancer cell survival and proliferation, causing apoptosis, cell cycle arrest, endoplasmic reticulum stress, and metabolic stress due to the inhibition of molecules like heat shock protein 90 and cyclin-dependent kinases. Ritonavir also causes resistant cells to become sensitized to anticancer drugs like gemcitabine or docetaxel. These findings indicate that repurposing ritonavir, either on its own or in combination with other medications, could be a promising approach for treating various diseases. This is particularly relevant in cancer therapy, where ritonavir repurposing is the central focus of this review.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vale</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1283-1042</Identifier><AffiliationInfo><Affiliation>PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Curr Oncol</MedlineTA><NlmUniqueID>9502503</NlmUniqueID><ISSNLinking>1198-0052</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemosensitization</Keyword><Keyword MajorTopicYN="N">drug repurposing</Keyword><Keyword MajorTopicYN="N">oncology</Keyword><Keyword MajorTopicYN="N">ritonavir</Keyword><Keyword MajorTopicYN="N">translational medicine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39451754</ArticleId><ArticleId IdType="pmc">PMC11505664</ArticleId><ArticleId IdType="doi">10.3390/curroncol31100450</ArticleId><ArticleId IdType="pii">curroncol31100450</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DrugBank  Ritonavir.  [(accessed on 9 July 2024)].  Available online:  https://go.drugbank.com/drugs/DB00503.</Citation></Reference><Reference><Citation>Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A.M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) Aids. 1996;10:995–999. doi: 10.1097/00002030-199610090-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-199610090-00010</ArticleId><ArticleId IdType="pubmed">8853733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempf D.J., Norbeck D.W., Codacovi L., Wang X.C., Kohlbrenner W.E., Wideburg N.E., Paul D.A., Knigge M.F., Vasavanonda S., Craig-Kennard A., et al. Structure-based, C2 symmetric inhibitors of HIV protease. J. Med. Chem. 1990;33:2687–2689. doi: 10.1021/jm00172a002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00172a002</ArticleId><ArticleId IdType="pubmed">2213822</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitesell J.K. C2 symmetry and asymmetric induction. Chem. Rev. 1989;89:1581–1590. doi: 10.1021/cr00097a012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr00097a012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull M.W., Montaner J.S. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 2011;43:375–388. doi: 10.3109/07853890.2011.572905.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07853890.2011.572905</ArticleId><ArticleId IdType="pubmed">21501034</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  NORVIR (Ritonavir)  [(accessed on 9 July 2024)]; Available online:  www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf.</Citation></Reference><Reference><Citation>Lledó-García R., Nácher A., Prats-García L., Casabó V.G., Merino-Sanjuán M. Bioavailability and pharmacokinetic model for ritonavir in the rat. J. Pharm. Sci. 2007;96:633–643. doi: 10.1002/jps.20683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.20683</ArticleId><ArticleId IdType="pubmed">17078039</ArticleId></ArticleIdList></Reference><Reference><Citation>Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V., et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med. 1995;333:1528–1533. doi: 10.1056/NEJM199512073332303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199512073332303</ArticleId><ArticleId IdType="pubmed">7477167</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson K.B., Wang K., Delille C., Otofokun I., Acosta E.P. Pharmacokinetic enhancers in HIV therapeutics. Clin. Pharmacokinet. 2014;53:865–872. doi: 10.1007/s40262-014-0167-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-014-0167-9</ArticleId><ArticleId IdType="pubmed">25164142</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Norvir.  [(accessed on 11 July 2024)].  Available online:  www.ema.europa.eu/en/documents/product-information/norvir-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Greenblatt D.J., Harmatz J.S. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug–drug interaction studies. Br. J. Clin. Pharmacol. 2015;80:342–350. doi: 10.1111/bcp.12668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12668</ArticleId><ArticleId IdType="pmc">PMC4574820</ArticleId><ArticleId IdType="pubmed">25923589</ArticleId></ArticleIdList></Reference><Reference><Citation>Loos N.H.C., Beijnen J.H., Schinkel A.H. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? Int. J. Mol. Sci. 2022;23:9866. doi: 10.3390/ijms23179866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23179866</ArticleId><ArticleId IdType="pmc">PMC9456214</ArticleId><ArticleId IdType="pubmed">36077262</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzolini C., Gibbons S., Khoo S., Back D. Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. J. Antimicrob. Chemother. 2016;71:1755–1758. doi: 10.1093/jac/dkw032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw032</ArticleId><ArticleId IdType="pubmed">26945713</ArticleId></ArticleIdList></Reference><Reference><Citation>Loos N.H.C., Beijnen J.H., Schinkel A.H. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed. Pharmacother. 2023;162:114636. doi: 10.1016/j.biopha.2023.114636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.114636</ArticleId><ArticleId IdType="pmc">PMC10065864</ArticleId><ArticleId IdType="pubmed">37004323</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewe J., Gutmann H., Fricker G., Török M., Beglinger C., Huwyler J. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol. 1999;57:1147–1152. doi: 10.1016/S0006-2952(99)00026-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-2952(99)00026-X</ArticleId><ArticleId IdType="pubmed">11230802</ArticleId></ArticleIdList></Reference><Reference><Citation>Storch C.H., Theile D., Lindenmaier H., Haefeli W.E., Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 2007;73:1573–1581. doi: 10.1016/j.bcp.2007.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2007.01.027</ArticleId><ArticleId IdType="pubmed">17328866</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Zhang Y., Unadkat J.D., Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2) J. Pharmacol. Exp. Ther. 2004;310:334–341. doi: 10.1124/jpet.104.065342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.104.065342</ArticleId><ArticleId IdType="pubmed">15007102</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert P., Ye Z.W., Stieger B., Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010;40:163–176. doi: 10.3109/00498250903509375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00498250903509375</ArticleId><ArticleId IdType="pubmed">20102298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Tang L.V. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication. J. Proteome Res. 2021;20:49–59. doi: 10.1021/acs.jproteome.0c00526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00526</ArticleId><ArticleId IdType="pubmed">33347311</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis S., Metzendorf M.I., Kuehn R., Popp M., Gagyor I., Kranke P., Meybohm P., Skoetz N., Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst. Rev. 2023;11:Cd015395. doi: 10.1002/14651858.CD015395.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD015395.pub3</ArticleId><ArticleId IdType="pmc">PMC10688265</ArticleId><ArticleId IdType="pubmed">38032024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N. Engl. J. Med. 2022;386:1397–1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid.  [(accessed on 16 July 2024)]; Available online:  www.fda.gov/media/155050/download.</Citation></Reference><Reference><Citation>WHO  Therapeutics and COVID-19: Living Guideline, 10 November 2023.  [(accessed on 16 July 2024)].  Available online:  https://app.magicapp.org/#/guideline/nBkO1E.</Citation></Reference><Reference><Citation>Shah M.M., Joyce B., Plumb I.D., Sahakian S., Feldstein L.R., Barkley E., Paccione M., Deckert J., Sandmann D., Hagen M.B., et al. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir against Hospitalization in Adults with Coronavirus Disease 2019. Clin. Infect. Dis. 2024;79:108–110. doi: 10.1093/cid/ciae105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae105</ArticleId><ArticleId IdType="pubmed">38411622</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Xiang H., He B., Zhang Q., Peng W. Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis. J. Glob. Health. 2023;13:06032. doi: 10.7189/jogh.13.06032.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.13.06032</ArticleId><ArticleId IdType="pmc">PMC10357131</ArticleId><ArticleId IdType="pubmed">37469290</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaka A., Yoshida Y., Yoshida T., Murakami A., Abe K., Ohuchi K., Kawakami T., Watanabe D., Hoshino T., Sawara K., et al. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1. Intern. Med. 2018;57:2807–2812. doi: 10.2169/internalmedicine.0810-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.0810-18</ArticleId><ArticleId IdType="pmc">PMC6207834</ArticleId><ArticleId IdType="pubmed">29780135</ArticleId></ArticleIdList></Reference><Reference><Citation>Flisiak R., Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert. Rev. Gastroenterol. Hepatol. 2017;11:559–567. doi: 10.1080/17474124.2017.1309284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474124.2017.1309284</ArticleId><ArticleId IdType="pubmed">28317409</ArticleId></ArticleIdList></Reference><Reference><Citation>Poordad F., Agarwal K., Younes Z., Cohen D., Xie W., Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin. Infect. Dis. 2015;60:608–610. doi: 10.1093/cid/ciu865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu865</ArticleId><ArticleId IdType="pubmed">25365973</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd-Elsalam S., Abo-Amer Y.E., El-Abgeegy M., Elshweikh S.A., Elsergany H.F., Ahmed R., Elkadeem M., Hawash N., Soliman S., Badawi R., et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience. Medicine. 2020;99:e21972. doi: 10.1097/MD.0000000000021972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000021972</ArticleId><ArticleId IdType="pmc">PMC7572016</ArticleId><ArticleId IdType="pubmed">33080669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronina O., Durlik M., Wawrzynowicz-Syczewska M., Buivydiene A., Katzarov K., Kupcinskas L., Tolmane I., Karpińska E., Pisula A., Karwowska K.M., et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Ann. Transpl. 2017;22:199–207. doi: 10.12659/AOT.903535.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AOT.903535</ArticleId><ArticleId IdType="pubmed">28386057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z., de Man R.A., Kamar N., Pan Q. Chronic hepatitis E: Advancing research and patient care. J. Hepatol. 2022;77:1109–1123. doi: 10.1016/j.jhep.2022.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.05.006</ArticleId><ArticleId IdType="pubmed">35605741</ArticleId></ArticleIdList></Reference><Reference><Citation>Primadharsini P.P., Nagashima S., Nishiyama T., Takahashi M., Murata K., Okamoto H. Development of Recombinant Infectious Hepatitis E Virus Harboring the nanoKAZ Gene and Its Application in Drug Screening. J. Virol. 2022;96:e0190621. doi: 10.1128/jvi.01906-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01906-21</ArticleId><ArticleId IdType="pmc">PMC8941883</ArticleId><ArticleId IdType="pubmed">35107380</ArticleId></ArticleIdList></Reference><Reference><Citation>Primadharsini P.P., Nagashima S., Takahashi M., Murata K., Okamoto H. Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin. Viruses. 2022;14:2440. doi: 10.3390/v14112440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112440</ArticleId><ArticleId IdType="pmc">PMC9697947</ArticleId><ArticleId IdType="pubmed">36366538</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira-Chioccola V.L., Vidal J.E., Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4:1363–1379. doi: 10.2217/fmb.09.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.09.89</ArticleId><ArticleId IdType="pubmed">19995194</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-El-Naga I.F., El Kerdany E.D., Mady R.F., Shalaby T.I., Zaytoun E.M. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitol. Int. 2017;66:735–747. doi: 10.1016/j.parint.2017.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parint.2017.08.007</ArticleId><ArticleId IdType="pubmed">28838776</ArticleId></ArticleIdList></Reference><Reference><Citation>Beld L., Jung H., Bulman C.A., Rosa B.A., Fischer P.U., Janetka J.W., Lustigman S., Sakanari J.A., Mitreva M. Aspartyl Protease Inhibitors as Anti-Filarial Drugs. Pathogens. 2022;11:707. doi: 10.3390/pathogens11060707.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11060707</ArticleId><ArticleId IdType="pmc">PMC9227574</ArticleId><ArticleId IdType="pubmed">35745561</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves É.A.R., de Miranda M.G., Borges T.K., Magalhães K.G., Muniz-Junqueira M.I. Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate immune response triggered by Leishmania in macrophages: The role of NF-κB and PPAR-γ. Int. Immunopharmacol. 2015;24:314–324. doi: 10.1016/j.intimp.2014.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2014.12.025</ArticleId><ArticleId IdType="pubmed">25545854</ArticleId></ArticleIdList></Reference><Reference><Citation>Brilhante R.S., Caetano É.P., Riello G.B., Guedes G.M., Castelo-Branco Dde S., Fechine M.A., Oliveira J.S., Camargo Z.P., Mesquita J.R., Monteiro A.J., et al. Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro. Braz. J. Infect. Dis. 2016;20:155–159. doi: 10.1016/j.bjid.2015.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2015.11.003</ArticleId><ArticleId IdType="pmc">PMC9427650</ArticleId><ArticleId IdType="pubmed">26748233</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Putten E., Wosikowski K., Beijnen J.H., Imre G., Freund C.R. Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel. Cancer Drug Resist. 2024;7:3. doi: 10.20517/cdr.2023.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.20517/cdr.2023.136</ArticleId><ArticleId IdType="pmc">PMC10838382</ArticleId><ArticleId IdType="pubmed">38318527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikezoe T., Hisatake Y., Takeuchi T., Ohtsuki Y., Yang Y., Said J.W., Taguchi H., Koeffler H.P. HIV-1 protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004;64:7426–7431. doi: 10.1158/0008-5472.CAN-03-2677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2677</ArticleId><ArticleId IdType="pubmed">15492266</ArticleId></ArticleIdList></Reference><Reference><Citation>Staal J., Beyaert R. Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications. Cells. 2018;7:122. doi: 10.3390/cells7090122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7090122</ArticleId><ArticleId IdType="pmc">PMC6162478</ArticleId><ArticleId IdType="pubmed">30158439</ArticleId></ArticleIdList></Reference><Reference><Citation>Skinner K.T., Palkar A.M., Hong A.L. Genetics of ABCB1 in Cancer. Cancers. 2023;15:4236. doi: 10.3390/cancers15174236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15174236</ArticleId><ArticleId IdType="pmc">PMC10487083</ArticleId><ArticleId IdType="pubmed">37686513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima T.S., Souza L.O., Iglesias-Gato D., Elversang J., Jørgensen F.S., Kallunki T., Røder M.A., Brasso K., Moreira J.M.A. Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. Front. Pharmacol. 2022;13:869461. doi: 10.3389/fphar.2022.869461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.869461</ArticleId><ArticleId IdType="pmc">PMC9203833</ArticleId><ArticleId IdType="pubmed">35721223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mita A.C., Figlin R., Mita M.M. Cabazitaxel: More than a new taxane for metastatic castrate-resistant prostate cancer? Clin. Cancer Res. 2012;18:6574–6579. doi: 10.1158/1078-0432.CCR-12-1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1584</ArticleId><ArticleId IdType="pubmed">23091116</ArticleId></ArticleIdList></Reference><Reference><Citation>de Weger V.A., Stuurman F.E., Hendrikx J.J.M.A., Moes J.J., Sawicki E., Huitema A.D.R., Nuijen B., Thijssen B., Rosing H., Keessen M., et al. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. Eur. J. Cancer. 2017;86:217–225. doi: 10.1016/j.ejca.2017.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2017.09.010</ArticleId><ArticleId IdType="pubmed">29031170</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishampayan U.N., Keessen M., Heath E.I., Dreicer R., Buchler T., Árkosy P.F., Csoszi T., Wiechno P.J., Kholtobin D., Kopyltsov E., et al. A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC) J. Clin. Oncol. 2022;40:5016. doi: 10.1200/JCO.2022.40.16_suppl.5016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.16_suppl.5016</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Ng A.S.N., Mak V.C.Y., Chan K.K.L., Cheung A.N.Y., Cheung L.W.T. Strategic Combination Therapies for Ovarian Cancer. Curr. Cancer Drug Targets. 2020;20:573–585. doi: 10.2174/1568009620666200511084007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568009620666200511084007</ArticleId><ArticleId IdType="pubmed">32392113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S., Bryant C.S., Chamala S., Qazi A., Seward S., Pal J., Steffes C.P., Weaver D.W., Morris R., Malone J.M., et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol. Cancer. 2009;8:26. doi: 10.1186/1476-4598-8-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-8-26</ArticleId><ArticleId IdType="pmc">PMC2691728</ArticleId><ArticleId IdType="pubmed">19386116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vélez-Cruz R., Johnson D.G. The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts. Int. J. Mol. Sci. 2017;18:1776. doi: 10.3390/ijms18081776.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18081776</ArticleId><ArticleId IdType="pmc">PMC5578165</ArticleId><ArticleId IdType="pubmed">28812991</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimha A.M., Kaulich M., Shapiro G.S., Choi Y.J., Sicinski P., Dowdy S.F. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. eLife. 2014;3:e02872. doi: 10.7554/eLife.02872.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.02872</ArticleId><ArticleId IdType="pmc">PMC4076869</ArticleId><ArticleId IdType="pubmed">24876129</ArticleId></ArticleIdList></Reference><Reference><Citation>Winterhoff B., Teoman A., Freyer L., Von Bismarck A., Dowdy S., Schmalfeldt B., Kumar S., Shridhar V. The HIV protease inhibitor ritonavir induces cell cycle arrest and apoptosis in the A2780 ovarian cancer cell line in vitro and in vivo. Gynecol. Oncol. 2013;130:e138. doi: 10.1016/j.ygyno.2013.04.393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2013.04.393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascio F., Spadaccino F., Rocchetti M.T., Castellano G., Stallone G., Netti G.S., Ranieri E. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers. 2021;13:3949. doi: 10.3390/cancers13163949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13163949</ArticleId><ArticleId IdType="pmc">PMC8394096</ArticleId><ArticleId IdType="pubmed">34439105</ArticleId></ArticleIdList></Reference><Reference><Citation>Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int. J. Womens Health. 2019;11:287–299. doi: 10.2147/IJWH.S197604.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJWH.S197604</ArticleId><ArticleId IdType="pmc">PMC6500433</ArticleId><ArticleId IdType="pubmed">31118829</ArticleId></ArticleIdList></Reference><Reference><Citation>Srirangam A., Wang M., Blum J., Einhorn L., Potter D.A. Ritonavir causes G1 arrest in non-small cell lung cancer (NSCLC), in part, by binding hsp90 and down-regulating Cdk4 and other Hsp90 client proteins. Cancer Res. 2005;65:534.</Citation></Reference><Reference><Citation>Rong B., Yang S. Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review) Int. J. Oncol. 2018;52:321–336. doi: 10.3892/ijo.2017.4214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2017.4214</ArticleId><ArticleId IdType="pubmed">29207057</ArticleId></ArticleIdList></Reference><Reference><Citation>Srirangam A., Milani M., Mitra R., Guo Z., Rodriguez M., Kathuria H., Fukuda S., Rizzardi A., Schmechel S., Skalnik D.G., et al. The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin. J. Thorac. Oncol. 2011;6:661–670. doi: 10.1097/JTO.0b013e31820c9e3c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0b013e31820c9e3c</ArticleId><ArticleId IdType="pmc">PMC3104055</ArticleId><ArticleId IdType="pubmed">21270666</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Hu C., Li H. Survivin as a novel target protein for reducing the proliferation of cancer cells. Biomed. Rep. 2018;8:399–406. doi: 10.3892/br.2018.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2018.1077</ArticleId><ArticleId IdType="pmc">PMC5920485</ArticleId><ArticleId IdType="pubmed">29725522</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora L., Kumar A.P., Arfuso F., Chng W.J., Sethi G. The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers. 2018;10:327. doi: 10.3390/cancers10090327.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers10090327</ArticleId><ArticleId IdType="pmc">PMC6162647</ArticleId><ArticleId IdType="pubmed">30217007</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney D., Davey M.G., Moloney B.M., Barry M.K., Sweeney K., McLaughlin R.P., Malone C.M., Lowery A.J., Kerin M.J. Breast cancer recurrence: Factors impacting occurrence and survival. Ir. J. Med. Sci. 2022;191:2501–2510. doi: 10.1007/s11845-022-02926-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-02926-x</ArticleId><ArticleId IdType="pmc">PMC9671998</ArticleId><ArticleId IdType="pubmed">35076871</ArticleId></ArticleIdList></Reference><Reference><Citation>Srirangam A., Mitra R., Wang M., Gorski J.C., Badve S., Baldridge L., Hamilton J., Kishimoto H., Hawes J., Li L., et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin. Cancer Res. 2006;12:1883–1896. doi: 10.1158/1078-0432.CCR-05-1167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-05-1167</ArticleId><ArticleId IdType="pmc">PMC2727652</ArticleId><ArticleId IdType="pubmed">16551874</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Prever L., Hirsch E., Gulluni F. Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. Cancers. 2021;13:3517. doi: 10.3390/cancers13143517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13143517</ArticleId><ArticleId IdType="pmc">PMC8304822</ArticleId><ArticleId IdType="pubmed">34298731</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Ma H., Yao J. ERα, A Key Target for Cancer Therapy: A Review. Onco Targets Ther. 2020;13:2183–2191. doi: 10.2147/OTT.S236532.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S236532</ArticleId><ArticleId IdType="pmc">PMC7073439</ArticleId><ArticleId IdType="pubmed">32210584</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Hendrikx J.J., Rottenberg S., Schellens J.H., Beijnen J.H., Huitema A.D. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. AAPS J. 2016;18:362–371. doi: 10.1208/s12248-015-9838-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-015-9838-1</ArticleId><ArticleId IdType="pmc">PMC4779112</ArticleId><ArticleId IdType="pubmed">26603889</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellens J.H., Malingré M.M., Kruijtzer C.M., Bardelmeijer H.A., van Tellingen O., Schinkel A.H., Beijnen J.H. Modulation of oral bioavailability of anticancer drugs: From mouse to man. Eur. J. Pharm. Sci. 2000;12:103–110. doi: 10.1016/S0928-0987(00)00153-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0928-0987(00)00153-6</ArticleId><ArticleId IdType="pubmed">11102737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrikx J.J., Lagas J.S., Song J.Y., Rosing H., Schellens J.H., Beijnen J.H., Rottenberg S., Schinkel A.H. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. Int. J. Cancer. 2016;138:758–769. doi: 10.1002/ijc.29812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29812</ArticleId><ArticleId IdType="pubmed">26297509</ArticleId></ArticleIdList></Reference><Reference><Citation>Gote V., Sharma A.D., Pal D. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. Int. J. Mol. Sci. 2021;22:1257. doi: 10.3390/ijms22031257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031257</ArticleId><ArticleId IdType="pmc">PMC7865449</ArticleId><ArticleId IdType="pubmed">33513992</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano M., Tanaka S., Sakaguchi M. Effects of normothermic microwave irradiation on CD44(+)/CD24(−) in breast cancer MDA-MB-231 and MCF-7 cell lines. Biosci. Biotechnol. Biochem. 2020;84:103–110. doi: 10.1080/09168451.2019.1670044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09168451.2019.1670044</ArticleId><ArticleId IdType="pubmed">31559912</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Othman N., Alhendi A., Ihbaisha M., Barahmeh M., Alqaraleh M., Al-Momany B.Z. Role of CD44 in breast cancer. Breast Dis. 2020;39:1–13. doi: 10.3233/BD-190409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/BD-190409</ArticleId><ArticleId IdType="pubmed">31839599</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder S., Murundi S., Crawford L., Putnam D. Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate. J. Control. Release. 2020;317:291–299. doi: 10.1016/j.jconrel.2019.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.11.027</ArticleId><ArticleId IdType="pubmed">31770573</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 2011;13:184–190. doi: 10.1038/ncb0311-184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb0311-184</ArticleId><ArticleId IdType="pmc">PMC3107571</ArticleId><ArticleId IdType="pubmed">21364565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato A. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. Onco Targets Ther. 2015;8:761–768. doi: 10.2147/OTT.S79776.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S79776</ArticleId><ArticleId IdType="pmc">PMC4399512</ArticleId><ArticleId IdType="pubmed">25914545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaedicke S., Firat-Geier E., Constantiniu O., Lucchiari-Hartz M., Freudenberg M., Galanos C., Niedermann G. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: Induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 2002;62:6901–6908.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460905</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato A., Asano T., Okubo K., Isono M., Asano T. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation. Cancer Sci. 2017;108:1194–1202. doi: 10.1111/cas.13242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13242</ArticleId><ArticleId IdType="pmc">PMC5480085</ArticleId><ArticleId IdType="pubmed">28342223</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Wan N., Liang Z., Zhang T., Jiang J. Ixazomib—The first oral proteasome inhibitor. Leuk. Lymphoma. 2019;60:610–618. doi: 10.1080/10428194.2018.1523398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2018.1523398</ArticleId><ArticleId IdType="pubmed">30614337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Shi C., He M., Xiong S., Xia X. Endoplasmic reticulum stress: Molecular mechanism and therapeutic targets. Signal Transduct. Target. Ther. 2023;8:352. doi: 10.1038/s41392-023-01570-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01570-w</ArticleId><ArticleId IdType="pmc">PMC10502142</ArticleId><ArticleId IdType="pubmed">37709773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato A., Asano T., Okubo K., Isono M., Asano T. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress. Oncol. Res. 2018;26:323–332. doi: 10.3727/096504017X14957929842972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096504017X14957929842972</ArticleId><ArticleId IdType="pmc">PMC7844765</ArticleId><ArticleId IdType="pubmed">28560953</ArticleId></ArticleIdList></Reference><Reference><Citation>Okubo K., Isono M., Asano T., Sato A. Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells. Anticancer. Res. 2019;39:5891–5901. doi: 10.21873/anticanres.13793.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.13793</ArticleId><ArticleId IdType="pubmed">31704813</ArticleId></ArticleIdList></Reference><Reference><Citation>Okubo K., ReßIng N., Schulz W.A., Hansen F.K., Asano T., Sato A. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells. Anticancer. Res. 2021;41:5987–5996. doi: 10.21873/anticanres.15417.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.15417</ArticleId><ArticleId IdType="pubmed">34848452</ArticleId></ArticleIdList></Reference><Reference><Citation>Batchu R.B., Gruzdyn O.V., Bryant C.S., Qazi A.M., Kumar S., Chamala S., Kung S.T., Sanka R.S., Puttagunta U.S., Weaver D.W., et al. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways. Pharmaceuticals. 2014;7:46–57. doi: 10.3390/ph7010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph7010046</ArticleId><ArticleId IdType="pmc">PMC3915194</ArticleId><ArticleId IdType="pubmed">24451403</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandigo A.C., Yuan W., Xu K., Gallagher P., Pang A., Guan Y.F., Shafi A.A., Thangavel C., Sheehan B., Bogdan D., et al. RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. Cancer Discov. 2021;11:2334–2353. doi: 10.1158/2159-8290.CD-20-1114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-1114</ArticleId><ArticleId IdType="pmc">PMC8419081</ArticleId><ArticleId IdType="pubmed">33879449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Zhao Y., Schwarz B., Mysliwietz J., Hartig R., Camaj P., Bao Q., Jauch K.W., Guba M., Ellwart J.W., et al. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. Int. J. Oncol. 2016;49:99–110. doi: 10.3892/ijo.2016.3512.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2016.3512</ArticleId><ArticleId IdType="pmc">PMC4902079</ArticleId><ArticleId IdType="pubmed">27177126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontious C., Kaul S., Hong M., Hart P.A., Krishna S.G., Lara L.F., Conwell D.L., Cruz-Monserrate Z. Cathepsin E expression and activity: Role in the detection and treatment of pancreatic cancer. Pancreatology. 2019;19:951–956. doi: 10.1016/j.pan.2019.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pan.2019.09.009</ArticleId><ArticleId IdType="pmc">PMC6829043</ArticleId><ArticleId IdType="pubmed">31582345</ArticleId></ArticleIdList></Reference><Reference><Citation>Keliher E.J., Reiner T., Earley S., Klubnick J., Tassa C., Lee A.J., Ramaswamy S., Bardeesy N., Hanahan D., Depinho R.A., et al. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia. 2013;15:684–693. doi: 10.1593/neo.13276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.13276</ArticleId><ArticleId IdType="pmc">PMC3689232</ArticleId><ArticleId IdType="pubmed">23814481</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer N.Y., Stanton R.C. The Warburg Effect, Lactate, and Nearly a Century of Trying to Cure Cancer. Semin. Nephrol. 2019;39:380–393. doi: 10.1016/j.semnephrol.2019.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semnephrol.2019.04.007</ArticleId><ArticleId IdType="pubmed">31300093</ArticleId></ArticleIdList></Reference><Reference><Citation>McBrayer S.K., Cheng J.C., Singhal S., Krett N.L., Rosen S.T., Shanmugam M. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: Implications for glucose transporter-directed therapy. Blood. 2012;119:4686–4697. doi: 10.1182/blood-2011-09-377846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-09-377846</ArticleId><ArticleId IdType="pmc">PMC3367873</ArticleId><ArticleId IdType="pubmed">22452979</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir P., Donaldson D., McMullin M.F., Crawford L. Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance. Cancers. 2023;15:1682. doi: 10.3390/cancers15061682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15061682</ArticleId><ArticleId IdType="pmc">PMC10046772</ArticleId><ArticleId IdType="pubmed">36980568</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalva-Aydemir S., Bajpai R., Martinez M., Adekola K.U., Kandela I., Wei C., Singhal S., Koblinski J.E., Raje N.S., Rosen S.T., et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin. Cancer Res. 2015;21:1161–1171. doi: 10.1158/1078-0432.CCR-14-1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1088</ArticleId><ArticleId IdType="pmc">PMC5571862</ArticleId><ArticleId IdType="pubmed">25542900</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaff L.R., Mellinghoff I.K. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329:574–587. doi: 10.1001/jama.2023.0023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.0023</ArticleId><ArticleId IdType="pmc">PMC11445779</ArticleId><ArticleId IdType="pubmed">36809318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kast R.E., Ramiro S., Lladó S., Toro S., Coveñas R., Muñoz M. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J. Neurooncol. 2016;126:425–431. doi: 10.1007/s11060-015-1996-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-015-1996-6</ArticleId><ArticleId IdType="pubmed">26603162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauschenbach L., Wieland A., Reinartz R., Kebir S., Till A., Darkwah Oppong M., Dobersalske C., Ullrich V., Ahmad A., Jabbarli R., et al. Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma. Eur. J. Cancer. 2020;140:130–139. doi: 10.1016/j.ejca.2020.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2020.09.017</ArticleId><ArticleId IdType="pubmed">33091717</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratton R., Tricarico P.M., Guimaraes R.L., Celsi F., Crovella S. Lopinavir/Ritonavir Treatment Induces Oxidative Stress and Caspaseindependent Apoptosis in Human Glioblastoma U-87 MG Cell Line. Curr. HIV Res. 2018;16:106–112. doi: 10.2174/1570162X16666180528100922.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570162X16666180528100922</ArticleId><ArticleId IdType="pubmed">29804534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu A., Granneman G.R., Bertz R.J. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 1998;35:275–291. doi: 10.2165/00003088-199835040-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-199835040-00002</ArticleId><ArticleId IdType="pubmed">9812178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>